Funding for this research was provided by:
UniversitĂ Cattolica del Sacro Cuore
Article History
Accepted: 19 September 2023
First Online: 23 October 2023
Declarations
:
: Dr. Lorusso reports consulting or advisory role at PharmaMar, Merck Serono, Novartis; speakers’ bureau fees from AstraZeneca, Clovis Oncology, PharmaMar, and Tesaro/GSK; research funding (to institution) from Clovis Oncology, Merck, PharmaMar, and Tesaro/GSK; personal financial interest in AstraZeneca, Clovis Oncology, PharmaMar, Roche, and Tesaro/GSK; Honoraria from AstraZeneca, Clovis Oncology, Genmab, Immunogen, Merck, Roche, and Tesaro/GSK; Expert testimony on behalf of Clovis Oncology. Dr. Mirza reports consulting or advisory role at Astra Zeneca, Biocad, BioNTech, Boehringer Ingelheim, Gilead, GSK, Karyopharm, Merck, Roche, Zailab, Regeneron, Exelixis; speakers’ bureau fees from AstraZeneca and GSK; research funding (to institution) from Apexigen, AstraZeneca, Deciphera (trial chair), GSK, and Ultimovacs; and personal financial interest in Karyopharm, Sera Prognostics (stocks/shares, member of Board of Directors). Dr. Giudice has nothing to disclose.